DK1429780T3 - Fremgangsmåde til behandling af mellemoreinfektioner - Google Patents

Fremgangsmåde til behandling af mellemoreinfektioner

Info

Publication number
DK1429780T3
DK1429780T3 DK02799587T DK02799587T DK1429780T3 DK 1429780 T3 DK1429780 T3 DK 1429780T3 DK 02799587 T DK02799587 T DK 02799587T DK 02799587 T DK02799587 T DK 02799587T DK 1429780 T3 DK1429780 T3 DK 1429780T3
Authority
DK
Denmark
Prior art keywords
middle ear
ear infections
treating middle
treating
infections
Prior art date
Application number
DK02799587T
Other languages
Danish (da)
English (en)
Inventor
Michael G Wall
Peter J Conroy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23261416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1429780(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Application granted granted Critical
Publication of DK1429780T3 publication Critical patent/DK1429780T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK02799587T 2001-09-21 2002-09-13 Fremgangsmåde til behandling af mellemoreinfektioner DK1429780T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32395101P 2001-09-21 2001-09-21

Publications (1)

Publication Number Publication Date
DK1429780T3 true DK1429780T3 (da) 2006-02-13

Family

ID=23261416

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02799587T DK1429780T3 (da) 2001-09-21 2002-09-13 Fremgangsmåde til behandling af mellemoreinfektioner

Country Status (19)

Country Link
US (8) US20030139382A1 (https=)
EP (1) EP1429780B1 (https=)
JP (1) JP2005504804A (https=)
KR (1) KR20040035760A (https=)
CN (1) CN1231218C (https=)
AT (1) ATE313328T1 (https=)
AU (1) AU2002333671B2 (https=)
BR (1) BR0212898A (https=)
CA (1) CA2459930C (https=)
CY (1) CY1104988T1 (https=)
DE (1) DE60208216T2 (https=)
DK (1) DK1429780T3 (https=)
ES (1) ES2250739T3 (https=)
FR (1) FR13C0012I2 (https=)
MX (1) MXPA04002576A (https=)
PL (1) PL212457B1 (https=)
RU (1) RU2295346C2 (https=)
WO (1) WO2003026671A1 (https=)
ZA (1) ZA200401847B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1231218C (zh) * 2001-09-21 2005-12-14 爱尔康公司 药物组合物在制备用于治疗中耳感染的药物中的用途
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
JP4792032B2 (ja) * 2004-08-13 2011-10-12 シェーリング−プラウ・リミテッド 抗生物質、トリアゾールおよびコルチコステロイドを含む薬学的処方物
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US7976873B2 (en) 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7959943B2 (en) * 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7993675B2 (en) * 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US20080139545A1 (en) * 2006-05-22 2008-06-12 Won-Taek Choe Formulation to treat ear infection
WO2008085913A1 (en) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
US8088095B2 (en) * 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
US20090263345A1 (en) * 2008-01-28 2009-10-22 Foresight Biotherapeutics, Inc. Otic compositions for the treatment of infections of the internal and external ear in mammals
US8030297B2 (en) 2008-05-14 2011-10-04 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders
ES2759373T3 (es) 2008-06-12 2020-05-08 Medtronic Xomed Inc Producto para el tratamiento de heridas crónicas con un sistema extracelular de solvatación de sustancias poliméricas
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
CN102112112A (zh) * 2008-07-21 2011-06-29 奥德纳米有限公司 用于治疗耳部病症的受控释放抗微生物组合物和方法
US8318817B2 (en) * 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
WO2010042427A2 (en) * 2008-10-06 2010-04-15 Microbial Defense Systems, Llc Antimicrobial composition and methods of making and using same
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
US8912236B2 (en) * 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
AU2010221438C1 (en) * 2009-03-03 2015-01-29 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
WO2010143186A1 (en) * 2009-06-08 2010-12-16 Otic Pharma Ltd. Otic foam formulations
EP2490722A4 (en) * 2009-10-21 2014-03-05 Otonomy Inc MODULATION OF THE TEMPERATURE OF GELIFICATION OF FORMULATIONS CONTAINING POLOXAMERS
AU2012253476B2 (en) 2011-05-10 2015-09-24 Next Science IP Holdings Pty Ltd Antimicrobial solid and methods of making and using same
EP2938327B1 (en) * 2012-12-26 2017-12-06 Otic Pharma Ltd. Foamable otic pharmaceutical compositions
JP2016534121A (ja) * 2013-08-27 2016-11-04 オトノミ—，インク． 小児の耳の病気の処置
US20150119371A1 (en) * 2013-10-30 2015-04-30 Micro Labs Limited Topical pharmaceutical compositions of antibiotics and steroidal anti inflammatory agents
WO2016004231A1 (en) 2014-07-03 2016-01-07 Otonomy, Inc. Sterilization of ciprofloxacin composition
US9393243B1 (en) * 2015-07-14 2016-07-19 Nilesh Parikh Topical Ciprofloxacin compositions
EP3512513A4 (en) 2016-09-16 2020-04-15 Otonomy, Inc. OTIC GEL FORMULATIONS FOR THE TREATMENT OF EXTERNAL OTITIS
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3134718A (en) * 1963-12-12 1964-05-26 Schering Corp Pregna-1,4-dienes and compositions containing same
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US5223493A (en) * 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
DE3704907A1 (de) * 1987-02-17 1988-08-25 Bayer Ag Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden
WO1990001933A1 (en) * 1988-08-26 1990-03-08 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
SU1811833A1 (ru) * 1989-06-09 1993-04-30 Vladimir I Ivanov Способ введения лекарственных средств в ухо 2
AU2672892A (en) * 1991-09-17 1993-04-27 Alcon Laboratories, Inc. Compositions containing quinolone antibiotics and sulfonate of polystyrol
ES2065846B1 (es) 1993-04-20 1995-10-01 Cusi Lab Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica.
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
ES2078175B1 (es) 1993-12-31 1996-10-16 Cusi Lab Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
ES2079320B1 (es) * 1994-05-17 1996-10-16 Cusi Lab Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones.
NZ309624A (en) 1995-06-06 1999-04-29 Bayer Ag Non-irritating, non-sensitizing, non-ototoxic (harmful to the ears) antibacterial compositions
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
DE19524691A1 (de) * 1995-07-06 1997-01-09 Liedtke Pharmed Gmbh Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen
ES2106680B1 (es) * 1995-08-03 1998-07-01 Vita Invest Sa Composiciones acuosas conteniendo ciprofloxacino y utilizacion y procedimiento correspondientes.
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
AR020660A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
WO2000018404A1 (en) 1998-09-30 2000-04-06 Alcon Laboratories, Inc. Antibiotic compositions for treatment of the eye, ear and nose
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
JP2003510263A (ja) * 1999-09-24 2003-03-18 アルコン，インコーポレイテッド シプロフロキサシンおよびデキサメタゾンを含有する局所用懸濁処方物
CN1231218C (zh) * 2001-09-21 2005-12-14 爱尔康公司 药物组合物在制备用于治疗中耳感染的药物中的用途

Also Published As

Publication number Publication date
ES2250739T3 (es) 2006-04-16
RU2295346C2 (ru) 2007-03-20
EP1429780B1 (en) 2005-12-21
PL212457B1 (pl) 2012-10-31
DE60208216D1 (de) 2006-01-26
US20160243029A1 (en) 2016-08-25
US20150374716A1 (en) 2015-12-31
CY1104988T1 (el) 2009-11-04
US20050059674A1 (en) 2005-03-17
CA2459930A1 (en) 2003-04-03
FR13C0012I2 (fr) 2014-02-14
PL369205A1 (en) 2005-04-18
EP1429780A1 (en) 2004-06-23
WO2003026671A1 (en) 2003-04-03
CA2459930C (en) 2009-11-10
BR0212898A (pt) 2004-10-13
CN1555267A (zh) 2004-12-15
US9149486B2 (en) 2015-10-06
RU2004111984A (ru) 2005-02-27
US9402805B1 (en) 2016-08-02
FR13C0012I1 (https=) 2013-04-05
US20080214513A1 (en) 2008-09-04
US20030139382A1 (en) 2003-07-24
AU2002333671B2 (en) 2006-07-20
MXPA04002576A (es) 2004-06-18
ATE313328T1 (de) 2006-01-15
DE60208216T2 (de) 2006-06-29
US20090156566A1 (en) 2009-06-18
US20160361324A1 (en) 2016-12-15
CN1231218C (zh) 2005-12-14
US20140363511A1 (en) 2014-12-11
ZA200401847B (en) 2005-05-25
JP2005504804A (ja) 2005-02-17
US8846650B2 (en) 2014-09-30
US9345714B2 (en) 2016-05-24
KR20040035760A (ko) 2004-04-29

Similar Documents

Publication Publication Date Title
DK1429780T3 (da) Fremgangsmåde til behandling af mellemoreinfektioner
TWI372611B (en) Device for providing treatment of an auditory system disorder and device for providing treatment of tinnitus
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
ATE340171T1 (de) Piperazinderivate zur behandlung bakterieller infektionen
NO20034056D0 (no) Proliferative sykdommer
DE60031248D1 (de) Elektroaktive pore
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
DE60215494D1 (de) Bicyclische, stickstoffhaltige heterocyclische derivate zur verwendung als antibakterielle mittel
DE60239707D1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
NO20014303D0 (no) JAK-3-inhibitorer for behandling av allergiske lidelser
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
BR0107691A (pt) Sapogeninas substituìdas e seu uso
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
CY1107780T1 (el) Μεθοδος για τη θεραπεια οφθαλμικων νεοαγγειακων ασθενειων
NO20015969D0 (no) Forbedret sklerittprotese for behandling av presbyopi og andre öyesykdommer
DK1381382T3 (da) Fremgangsmåder og præparater til behandling af öjensygdomme
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
CY1106409T1 (el) Παραγωγα κινολινης
DK1441761T3 (da) Fremgangsmåder til forebyggelse og behandling af flavivirus-infektion hos dyr
IL315142A (en) Methods and compositions for treating hearing loss
PT1140080E (pt) Utilizacao de riluzole no tratamento de traumatismos acusticos
SE0100374D0 (sv) Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof
ATE401337T1 (de) Antiangiogene polypeptide